Today's Stocks Driving Success For The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 68 points (-0.4%) at 17,105 as of Tuesday, Sept. 23, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,162 issues advancing vs. 1,797 declining with 186 unchanged.

The Drugs industry currently sits up 0.3% versus the S&P 500, which is down 0.2%. A company within the industry that increased today was Herbalife ( HLF), up 7.7%. On the negative front, top decliners within the industry include Grifols ( GRFS), down 3.5%, Sanofi ( SNY), down 1.9%, AbbVie ( ABBV), down 1.8% and Novo Nordisk A/S ( NVO), down 1.2%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Allergan ( AGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Allergan is up $4.54 (2.7%) to $170.66 on heavy volume. Thus far, 2.6 million shares of Allergan exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $164.38-$171.11 after having opened the day at $166.95 as compared to the previous trading day's close of $166.12.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $50.0 billion and is part of the health care sector. Shares are up 49.5% year-to-date as of the close of trading on Monday. Currently there are 6 analysts who rate Allergan a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Allergan Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Biogen Idec ( BIIB) is up $4.04 (1.2%) to $333.80 on average volume. Thus far, 477,775 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $327.68-$334.23 after having opened the day at $328.51 as compared to the previous trading day's close of $329.76.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $77.7 billion and is part of the health care sector. Shares are up 17.9% year-to-date as of the close of trading on Monday. Currently there are 12 analysts who rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Celgene ( CELG) is up $0.93 (1.0%) to $93.12 on average volume. Thus far, 1.7 million shares of Celgene exchanged hands as compared to its average daily volume of 4.3 million shares. The stock has ranged in price between $91.62-$93.30 after having opened the day at $91.80 as compared to the previous trading day's close of $92.19.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. Celgene has a market cap of $75.0 billion and is part of the health care sector. Shares are up 9.1% year-to-date as of the close of trading on Monday. Currently there are 18 analysts who rate Celgene a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, robust revenue growth, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Celgene Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Stocks Trade Mixed, Energy Shares Fall on Sharp Drop in Oil Prices

Stocks Trade Mixed, Energy Shares Fall on Sharp Drop in Oil Prices

Component Stocks Rise After Trump Reverses Decision on ZTE

Component Stocks Rise After Trump Reverses Decision on ZTE

Crude Slides as Russia Eases Cuts and U.S. Oil Producers Boost Rig Count

Crude Slides as Russia Eases Cuts and U.S. Oil Producers Boost Rig Count

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping